LEADING ARTICLE

Hepcidin and its role in iron absorption

K J Robson

Maintaining the correct iron balance is crucial to good health. Disorders of iron homeostasis have a global distribution. As iron is not actively excreted by the body, understanding the role of proteins involved in regulating iron uptake is essential to our understanding of disease involving iron homeostasis. Over the past 10 years, major advances have been made in understanding the genetics of iron metabolism and this has led to identification of a number of new proteins, including hepcidin, involved in iron homeostasis.

Iron uptake is essential to our understanding of disease involving iron homeostasis. Over the past 10 years, major advances have been made in understanding the genetics of iron metabolism and this has led to identification of a number of new proteins involved in iron homeostasis (reviewed by Clement Finch, in his review in 1994 on regulators of iron balance in humans, described the characteristics of the store and erythroid iron regulators. This was based on physiological observations. The store regulator is most probably the peptide hepcidin. The model predicted that the store regulator would regulate iron uptake from the proximal cells of the duodenum. On a daily basis, the store regulator would increase iron uptake until there were sufficient iron stores for erythropoiesis. To prevent iron overload, a feedback mechanism has to be invoked. It is essential that this uptake process is tightly regulated because mammals lack a means of excreting iron. In mammals, iron is lost through the sloughing of cells, and in females also through menstruation and childbirth. The store regulator therefore regulates iron in the same way that a room thermostat maintains a constant temperature. The erythroid regulator on the other hand is involved in situations where there is a larger requirement for iron. The predicted location for the erythroid regulator is bone marrow because it is this tissue that is highly sensitive to iron stores.

Several groups independently discovered hepcidin. Two groups found hepcidin while they were identifying novel antimicrobial peptides. Krause et al described a peptide that was synthesised by the liver that they called liver expressed antimicrobial peptide 1 (LEAP-1). Park et al identified a peptide they called hepactin (hepatic bactericidal protein) in urine. The human hepcidin gene (HAMP) comprises three exons and maps to the long arm of chromosome 19 (19q13). The human gene encodes a pre-propeptide of 84 amino acids. The signal peptide is cleaved to give the 60 amino acid form pro-hepcidin and this is further processed to give the 25 amino acid form hepcidin that is found both in blood and urine. Hepcidin is evolutionarily conserved; hepcidin genes have been found in fish. Eight of the 25 amino acids in hepcidin are cysteine residues. The 25 amino acid form has both antibacterial and antifungal activities, making hepcidin a member of the family of cysteine rich, cationic, antimicrobial peptides which includes the defensins. Members of this family of peptides have been shown to be involved in inflammation. Hepcidin has been shown to be a type II acute phase protein.

"The role of hepcidin in iron homeostasis was revealed by two French groups working independently"

The role of hepcidin in iron homeostasis was revealed by two French groups working independently. Pigeon et al isolated the murine hepcidin gene using a differential screening approach. They identified hepcidin because this mRNA was increased under conditions of dietary iron loading. Nicolas et al identified the murine hepcidin gene as having a role in iron homeostasis totally serendipitously. In generating USF2 null mice they accidentally removed the neighbouring hepcidin genes. These mice spontaneously became loaded with iron and the pattern of iron loading mimicked that seen in hereditary haemochromatosis (HH). That hepcidin rather than USF2 was involved in iron homeostasis was confirmed when mice transgenic for hepcidin were produced and were severely anaemic. There are two hepcidin genes in mice but only one in humans. Loss of functioning hepcidin genes in mice was associated with raised serum iron, decreased reticuloendothelial iron stores, and increased intestinal iron absorption.

Abbreviations: HH, hereditary haemochromatosis

Correspondence to: Dr K J Robson, Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, John Radcliffe Hospital, Oxford, OX3 9DS; kathryn.robson@molecular-medicine.oxford.ac.uk

Accepted for publication 10 December 2003

Administration of lipopolysaccharide, a classic inducer of the acute phase response, results in increased hepcidin expression. Anaemia induced by haemolysis or phlebotomy results in reduced hepcidin expression which is also observed as a response to hypoxia. These results provide the necessary link between iron homeostasis and anaemia of chronic disease. Anaemia of chronic disease is poorly understood and is found in patients with a broad spectrum of diseases, including viral and bacterial infections, malignancies, and rheumatological complaints. Such conditions exhibit a blunted erythropoietin response by erythroid precursors, decreased red blood cell survival, and abnormalities in both iron absorption and retention of iron by macrophages, restricting the availability of iron to erythroid precursors in the marrow. This has been demonstrated in a specific set of patients with large hepatic adenomas who have a severe refractory anaemia that resolves once the adenomas are removed. In anaemia of chronic disease, there is a decrease in circulating iron, increased reticuloendothelial iron, and decreased intestinal iron absorption, while the reverse is true for haemochromatosis. Bridle et al demonstrated that hepcidin mRNA levels in the livers of patients with HH were inappropriately low with respect to their iron stores. Further work by the group of Stremmel demonstrated a link between transferrin saturation and hepatic hepcidin expression in patients with HH. Hepcidin levels are inappropriately low in relation to plasma ferritin levels. The role of hepcidin in haemochromatosis was further confirmed when two families presenting with juvenile haemochromatosis, unlinked to the previously identified locus on chromosome 1, were found to have either a nonsense mutation in exon 2 or a frameshift mutation at the end of exon 2. Both of these mutations result in failure to synthesise hepcidin as this is entirely encoded by exon 3. Very recently, Merryweather-Clarke et al demonstrated a synergy between mutations in hepcidin and HFE resulting in haemochromatosis. The severity of the mutation in hepcidin determines whether the patient has juvenile or adult onset haemochromatosis. In a mouse model for haemochromatosis, constitutive expression reverses iron loading. In Hfe deficient mice there are alterations in expression of the homologues for ferroportin/IREG1, hepcidin, and the duodenal ferric reductase DCYTB. For more details on the role of hepcidin as a key regulator in iron metabolism and as a mediator in the anaemia of inflammation see the review by Ganz.

=" anaemia of chronic disease, there is a decrease in circulating iron, increased reticuloendothelial iron, and decreased intestinal iron absorption, while the reverse is true for haemochromatosis"

Therefore, to understand both the role of hepcidin in modifying expression of iron uptake in patients with haemochromatosis and its involvement in patients suffering from anaemia of chronic disease, it is important to be able to quantify circulating levels of pro-hepcidin and hepcidin. Thus far, measurement of hepcidin has been limited to a reverse transcription step and amplification using the polymerase chain reaction to determine hepcidin mRNA levels in the liver or what the receptor is in the gut that responds to hepcidin. It is of course possible that hepcidin interacts directly with proteins such as the basolateral transporter ferroportin/IREG1 and so controls the release of iron both from the duodenal enterocytes and macrophages. Patients with mutations in the ferroportin/IREG1 gene (SLC40A1) have been described and present with a hyperferritinaemia that has an autosomal dominant pattern of inheritance.

There are still many unanswered questions. We do not know what signals result in the increased synthesis of hepcidin by the liver or what the receptor is in the gut that responds to hepcidin. It is of course possible that hepcidin interacts directly with proteins such as the basolateral transporter ferroportin/IREG1 and so controls the release of iron both from the duodenal enterocytes and macrophages. Patients with mutations in the ferroportin/IREG1 gene (SLC40A1) have been described and present with a hyperferritinaemia that has an autosomal dominant pattern of inheritance.

The missing juvenile haemochromatogens gene product mapping to chromosome 1 may provide some of the missing links. The hepcidin gene is regulated both by CCAAT/enhancer binding protein α (C/EBPα) and interleukin 6. Neither of these genes map to chromosome 1. Very recently, a joint paper from the groups of Goldberg from Xenon Genetics Research and Papanikolaou from Greece have described a gene they call hemojuvelin which maps to chromosome 1; this is clearly the HJV gene. The gene product is unlikely to be the hepcidin receptor as it appears to modulate hepcidin expression. Hemojuvelin is predicted to be a transmembrane protein having both an RGD (Asp-Gly-Asp) motif and a partial von Willebrand factor type D domain. As might be expected, it is expressed in both adult and fetal liver but also in heart and skeletal muscle. It will be interesting to see how hemojuvelin contributes to iron homeostasis.

"It will be interesting to see how hemojuvelin contributes to iron homeostasis"

REFERENCES

Hepcidin and its role in iron absorption